196 related articles for article (PubMed ID: 17212760)
21. Assessment of vaccine potential of the Neisseria-specific protein NMB0938.
Sardiñas G; Climent Y; Rodríguez Y; González S; García D; Cobas K; Caballero E; Pérez Y; Brookes C; Taylor S; Gorringe A; Delgado M; Pajón R; Yero D
Vaccine; 2009 Nov; 27(49):6910-7. PubMed ID: 19751688
[TBL] [Abstract][Full Text] [Related]
22. Passive protection in the infant rat protection assay by sera taken before and after vaccination of teenagers with serogroup B meningococcal outer membrane vesicle vaccines.
Toropainen M; Saarinen L; Wedege E; Bolstad K; Mäkelä PH; Käyhty H
Vaccine; 2005 Sep; 23(40):4821-33. PubMed ID: 15970361
[TBL] [Abstract][Full Text] [Related]
23. Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process.
van de Waterbeemd B; Streefland M; van der Ley P; Zomer B; van Dijken H; Martens D; Wijffels R; van der Pol L
Vaccine; 2010 Jul; 28(30):4810-6. PubMed ID: 20483197
[TBL] [Abstract][Full Text] [Related]
24. Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.
Findlow J; Taylor S; Aase A; Horton R; Heyderman R; Southern J; Andrews N; Barchha R; Harrison E; Lowe A; Boxer E; Heaton C; Balmer P; Kaczmarski E; Oster P; Gorringe A; Borrow R; Miller E
Infect Immun; 2006 Aug; 74(8):4557-65. PubMed ID: 16861642
[TBL] [Abstract][Full Text] [Related]
25. Well-defined and potent liposomal meningococcal B vaccines adjuvated with LPS derivatives.
Arigita C; Luijkx T; Jiskoot W; Poelen M; Hennink WE; Crommelin DJ; Ley Pv; Els Cv; Kersten GF
Vaccine; 2005 Oct; 23(43):5091-8. PubMed ID: 15993990
[TBL] [Abstract][Full Text] [Related]
26. Antibody specificities and effect of meningococcal carriage in icelandic teenagers receiving the Norwegian serogroup B outer membrane vesicle vaccine.
Wedege E; Kuipers B; Bolstad K; van Dijken H; Frøholm LO; Vermont C; Caugant DA; van den Dobbelsteen G
Infect Immun; 2003 Jul; 71(7):3775-81. PubMed ID: 12819059
[TBL] [Abstract][Full Text] [Related]
27. A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial.
Marsay L; Dold C; Green CA; Rollier CS; Norheim G; Sadarangani M; Shanyinde M; Brehony C; Thompson AJ; Sanders H; Chan H; Haworth K; Derrick JP; Feavers IM; Maiden MC; Pollard AJ
J Infect; 2015 Sep; 71(3):326-37. PubMed ID: 25982025
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of immunological responses to recombinant Porin A protein (rPoA) from native strains of Neisseria meningitidis serogroups A and B using OMV as an adjuvant in BALB/c mice.
Afrough P; Bouzari S; Mousavi SF; Asadi Karam MR; Vaziri F; Fateh A; Behrouzi A; Malekan M; Siadat SD
Microb Pathog; 2017 Nov; 112():209-214. PubMed ID: 28942175
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity and tolerability in infants of a New Zealand epidemic strain meningococcal B outer membrane vesicle vaccine.
Wong SH; Lennon DR; Jackson CM; Stewart JM; Reid S; Ypma E; O'Hallahan JM; Oster P; Mulholland K; Martin DR
Pediatr Infect Dis J; 2009 May; 28(5):385-90. PubMed ID: 19384263
[TBL] [Abstract][Full Text] [Related]
30. Proteomic analysis of Neisseria lactamica and N eisseria meningitidis outer membrane vesicle vaccine antigens.
Vaughan TE; Skipp PJ; O'Connor CD; Hudson MJ; Vipond R; Elmore MJ; Gorringe AR
Vaccine; 2006 Jun; 24(25):5277-93. PubMed ID: 16682101
[TBL] [Abstract][Full Text] [Related]
31. Properties and clinical performance of vaccines containing outer membrane vesicles from Neisseria meningitidis.
Holst J; Martin D; Arnold R; Huergo CC; Oster P; O'Hallahan J; Rosenqvist E
Vaccine; 2009 Jun; 27 Suppl 2():B3-12. PubMed ID: 19481313
[TBL] [Abstract][Full Text] [Related]
32. Understanding the immune responses to the meningococcal strain-specific vaccine MeNZB measured in studies of infants.
Ruijne N; Lea RA; O'Hallahan J; Oster P; Martin D
Clin Vaccine Immunol; 2006 Jul; 13(7):797-801. PubMed ID: 16829618
[TBL] [Abstract][Full Text] [Related]
33. Characterisation and immune responses to meningococcal recombinant porin complexes incorporated into liposomes.
Sánchez S; Abel A; Marzoa J; Gorringe A; Criado T; Ferreirós CM
Vaccine; 2009 Aug; 27(39):5338-43. PubMed ID: 19607954
[TBL] [Abstract][Full Text] [Related]
34. Heterologous prime-boost strategy to overcome weak immunogenicity of two serosubtypes in hexavalent Neisseria meningitidis outer membrane vesicle vaccine.
Luijkx T; van Dijken H; van Els C; van den Dobbelsteen G
Vaccine; 2006 Mar; 24(10):1569-77. PubMed ID: 16298029
[TBL] [Abstract][Full Text] [Related]
35. Cross-reactivity of antibodies against PorA after vaccination with a meningococcal B outer membrane vesicle vaccine.
Vermont CL; van Dijken HH; Kuipers AJ; van Limpt CJ; Keijzers WC; van der Ende A; de Groot R; van Alphen L; van den Dobbelsteen GP
Infect Immun; 2003 Apr; 71(4):1650-5. PubMed ID: 12654777
[TBL] [Abstract][Full Text] [Related]
36. Immuno-proteomic analysis of human immune responses to experimental Neisseria meningitidis outer membrane vesicle vaccines identifies potential cross-reactive antigens.
Williams JN; Weynants V; Poolman JT; Heckels JE; Christodoulides M
Vaccine; 2014 Mar; 32(11):1280-6. PubMed ID: 24486354
[TBL] [Abstract][Full Text] [Related]
37. Antigen-specific T-cell responses in humans after intranasal immunization with a meningococcal serogroup B outer membrane vesicle vaccine.
Oftung F; Naess LM; Wetzler LM; Korsvold GE; Aase A; Høiby EA; Dalseg R; Holst J; Michaelsen TE; Haneberg B
Infect Immun; 1999 Feb; 67(2):921-7. PubMed ID: 9916109
[TBL] [Abstract][Full Text] [Related]
38. IgG antibody subclass responses determined by immunoblot in infants' sera following vaccination with a meningococcal recombinant hexavalent PorA OMV vaccine.
Martin S; Sadler F; Borrow R; Dawson M; Fox A; Cartwright K
Vaccine; 2001 Aug; 19(31):4404-8. PubMed ID: 11483265
[TBL] [Abstract][Full Text] [Related]
39. Meningococcal outer membrane vesicle vaccine given intranasally can induce immunological memory and booster responses without evidence of tolerance.
Bakke H; Lie K; Haugen IL; Korsvold GE; Høiby EA; Naess LM; Holst J; Aaberge IS; Oftung F; Haneberg B
Infect Immun; 2001 Aug; 69(8):5010-5. PubMed ID: 11447180
[TBL] [Abstract][Full Text] [Related]
40. Improving the immunogenicity of a trivalent Neisseria meningitidis native outer membrane vesicle vaccine by genetic modification.
Zhang L; Wen Z; Lin J; Xu H; Herbert P; Wang XM; Mehl JT; Ahl PL; Dieter L; Russell R; Kosinski MJ; Przysiecki CT
Vaccine; 2016 Jul; 34(35):4250-4256. PubMed ID: 27269057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
